

## **ELFABRIO (pegunigalsidase alfa-iwxj)**

### **RATIONALE FOR INCLUSION IN PA PROGRAM**

#### **Background**

Fabry disease is caused by deficiency of the lysosomal enzyme alpha-galactosidase A. Clinical manifestations of Fabry disease include neuropathy, renal failure, cardiomyopathy, and cerebrovascular accidents. Elfabrio provides an exogenous source of alpha-galactosidase A. Elfabrio is internalized and transported into lysosomes where it is thought to exert enzymatic activity and reduce accumulated globotriaosylceramide (Gb3) (1).

#### **Regulatory Status**

FDA-approved indication: Elfabrio is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease (1).

Elfabrio has a boxed warning regarding hypersensitivity reactions, including anaphylaxis. Prior to Elfabrio administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. If severe allergic or anaphylactic reactions occur, immediately discontinue Elfabrio and initiate appropriate medical treatment (1).

Infusion-associated reactions have been reported in Elfabrio-treated patients. Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from infusion reactions. Appropriate medical support measures should be readily available when Elfabrio is administered because of the potential for severe infusion reactions (1).

The safety and effectiveness of Elfabrio in pediatric patients less than 18 years of age have not been established (1).

#### **Summary**

Elfabrio is indicated for use in patients with Fabry disease. Elfabrio provides an exogenous source of alpha-galactosidase A and reduces accumulated Gb3. Life-threatening anaphylactic and severe allergic reactions have been observed in some patients during Elfabrio infusions. The safety and effectiveness of Elfabrio in pediatric patients less than 18 years of age have not been established (1).



**BlueCross  
BlueShield**

Federal Employee Program.

**ELFABRIO  
(pegunigalsidase alfa-iwxj)**

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Elfabrio while maintaining optimal therapeutic outcomes.

**References**

1. Elfabrio [package insert]. Cary, NC: Chiesi USA, Inc.; May 2024.